Sporadic ALS Initiation Biology: Deep Phenotyping of At-Risk Cohorts

Experiment Proposal: Sporadic ALS Initiation Biology

Gap Addressed

ALS Knowledge Gap #1: What triggers sporadic ALS initiation in patients with no known genetic variants?

ALS Knowledge Gap #2: Why do genetically identical individuals with identical mutations (e.g., C9orf72 repeat expansions) exhibit such variable age at onset and progression rates?

ALS Knowledge Gap #3: Can the pre-symptomatic window be detected through biomarker signatures before clinical onset, enabling preventive intervention?

Hypothesis

Sporadic ALS initiates through a convergence of environmental exposures, epigenetic modifications, and cumulative cellular stress that create a permissive state for TDP-43 pathology in vulnerable motor neurons—identifiable through multi-omics profiling before clinical onset[@ratti2023].

TDP-43 Pathology: The Central Mechanism

TDP-43 Biology in Normal Neurons

[TDP-43 (TAR DNA-binding protein 43)](https://en.wikipedia.org/wiki/TAR_DNA-binding_protein_43) is a 414-amino acid nuclear protein encoded by the TARDBP gene. Under normal conditions, TDP-43:

• Binds to thousands of RNA targets, regulating alternative splicing and mRNA stability
• Participates in stress granule dynamics
• Regulates translation of specific neuronal transcripts
• Maintains nuclear homeostasis through autoregulation

In 95% of ALS cases and 50% of frontotemporal dementia (FTD) cases, TDP-43 becomes mislocalized to the cytoplasm, hyperphosphorylated, and aggregated into inclusions[@neumann2006][@kim2023].

The Seeding and Spreading Model

...

Experiment Proposal: Sporadic ALS Initiation Biology

Gap Addressed

ALS Knowledge Gap #1: What triggers sporadic ALS initiation in patients with no known genetic variants?

ALS Knowledge Gap #2: Why do genetically identical individuals with identical mutations (e.g., C9orf72 repeat expansions) exhibit such variable age at onset and progression rates?

ALS Knowledge Gap #3: Can the pre-symptomatic window be detected through biomarker signatures before clinical onset, enabling preventive intervention?

Hypothesis

Sporadic ALS initiates through a convergence of environmental exposures, epigenetic modifications, and cumulative cellular stress that create a permissive state for TDP-43 pathology in vulnerable motor neurons—identifiable through multi-omics profiling before clinical onset[@ratti2023].

TDP-43 Pathology: The Central Mechanism

TDP-43 Biology in Normal Neurons

[TDP-43 (TAR DNA-binding protein 43)](https://en.wikipedia.org/wiki/TAR_DNA-binding_protein_43) is a 414-amino acid nuclear protein encoded by the TARDBP gene. Under normal conditions, TDP-43:

• Binds to thousands of RNA targets, regulating alternative splicing and mRNA stability
• Participates in stress granule dynamics
• Regulates translation of specific neuronal transcripts
• Maintains nuclear homeostasis through autoregulation

In 95% of ALS cases and 50% of frontotemporal dementia (FTD) cases, TDP-43 becomes mislocalized to the cytoplasm, hyperphosphorylated, and aggregated into inclusions[@neumann2006][@kim2023].

The Seeding and Spreading Model

Why Motor Neurons Are Vulnerable

Large cell size: Motor neurons have axons up to 1 meter long, requiring intense axonal transport and protein synthesis. This creates high metabolic stress.

Unique splicing patterns: Motor neurons express specific TDP-43-dependent splice variants that are disrupted in disease.

Mitochondrial density: High energy demands make motor neurons particularly sensitive to mitochondrial dysfunction[@khalil2024].

Non-coding repeat RNA toxicity: In familial ALS (C9orf72), expanded G4C2 repeats produce toxic dipeptide repeat proteins (DPRs) that disrupt nucleocytoplasmic transport.

Multi-Omics Profiling Framework

Proteomics

Rationale: Plasma and CSF proteomics can identify circulating biomarkers of neuronal stress.

Key Targets:

• [Neurofilament light chain (NfL)](https://pubmed.ncbi.nlm.nih.gov/38063421/): Validated biomarker of neuroaxonal injury. Elevated years before clinical onset in ALS mutation carriers[@rotunno2023].
• [Neurofilament heavy chain (NfH)]: Complementary to NfL, provides specificity.
• [TDP-43 fragments**: C-terminal fragments (35kDa) detectable in CSF of ALS patients.
• [Phosphorylated neurofilament (pNfH)]: Correlates with disease progression rate.

Assay Platform: Simoa HD-X Analyzer (Quanterix) for ultra-sensitive NfL detection. Target sensitivity: 0.1 pg/mL.

Metabolomics

CSF Metabolome: Characterize metabolic states that precede clinical onset.

Target Metabolites:

• Energy metabolites: Pyruvate, lactate, ATP/ADP ratio
• Amino acids: Glutamate (excitotoxicity), branched-chain amino acids
• Lipid species: Ceramides, phospholipids (membrane integrity)
• Oxidative stress markers: 8-OHdG, 4-HNE adducts

Transcriptomics

Whole-blood RNA-seq: Capture immune and glial cell transcriptional signatures.

Key Signatures:

• Innate immune activation (TREM2 pathway upregulation)
• Mitochondrial stress response genes (HSPA1B, HSP90AA1)
• Inflammatory cytokines (IL-6, TNF-alpha)
• Cytoskeletal genes (NEFL, NEFH)

Single-cell RNA-seq of peripheral blood mononuclear cells (PBMCs):

• Monocyte activation state (CD14+, CD16+)
• T-cell exhaustion markers
• NK cell dysfunction

Epigenomics

DNA methylation and chromatin state changes reflect cumulative exposure and gene-environment interactions[@pozzoli2024].

Approaches:

• [Whole-genome bisulfite sequencing (WGBS)](https://en.wikipedia.org/wiki/Bisulfite_sequencing) of peripheral blood
• ATAC-seq for chromatin accessibility in iPSC-derived motor neurons
• Long-read nanopore sequencing for methylation detection

Candidate Regions:

• SOD1, C9orf72, FUS promoter regions
• Inflammation-related genes (IL6, TNF)
• Stress response genes (HSP70 family)

Multi-Modal Integration

Environmental Risk Factors

Mechanistic Links to ALS Initiation

Environmental exposures may act as "second hits" that push genetically susceptible neurons over the threshold into degeneration[@suhara2023].

| Exposure | Mechanism | Evidence Level | Biomarker |
|----------|-----------|----------------|----------|
| Heavy metals (lead, mercury) | Oxidative stress, mitochondrial dysfunction | Moderate | Blood/urine metal levels |
| Pesticides/Herbicides | Mitochondrial toxicity, excitotoxicity | Strong | Occupational history + biomarkers |
| Traumatic brain injury | Neuroinflammation, BBB disruption | Moderate | Medical records + GFAP |
| Smoking | Oxidative stress, vascular dysfunction | Moderate | Cotinine levels |
| Physical exertion | Increased metabolic stress | Conflicting | Biomarker panel |
| Organic solvents | Neurotoxicity, protein aggregation | Moderate | Exposure biomarkers |
| Electromagnetic fields | Unknown | Weak | N/A |

Exposure Assessment Protocol

Structured questionnaire: Lifetime occupational and residential exposure history

Biological samples: Hair重金属, toenail selenium, urine organics

Geographic modeling: GIS-based pesticide use data

Biological dosimetry: DNA adducts for chemical exposures

Cohort Assembly Strategy

At-Risk Population Definition

Longitudinal Follow-Up Protocol

Visit Schedule: Months 0, 6, 12, 18, 24, 36, 48, 60

Assessments at Each Visit:

• Neurological examination (including upper motor neuron signs)
• ALSFRS-R (revised ALS Functional Rating Scale)
• Timed motor tests (9-hole peg, grip strength, FVC)
• Blood/CSF collection for biomarker panel
• Optional: MRI brain and spinal cord (annual)

Baseline Multi-Omics Panel

| Modality | Sample | Platform | Reads/Samples |
|----------|--------|----------|---------------|
| Plasma proteomics | EDTA plasma | SomaScan 7K | 7,000 proteins |
| CSF proteomics | Lumbar puncture | Olink Explore | 3,000 proteins |
| Metabolomics | Plasma + CSF | LC-MS/MS | 500 metabolites |
| RNA-seq | Whole blood | NovaSeq | 50M reads |
| scRNA-seq | PBMCs | 10x Genomics | 10,000 cells |
| DNA methylomics | Whole blood | EPIC array | 850K sites |
| WGS | Whole blood | NovaSeq | 40x depth |

Biomarker Discovery Pipeline

Machine Learning Integration

Data Integration Strategy: Federated learning across cohorts to preserve privacy while building predictive models.

Model Architecture:

Modality-specific encoders (proteins, metabolites, transcripts, methylation)

Cross-modal attention layer

Temporal sequence modeling (LSTM) for longitudinal trajectories

Risk score output (0-100 continuous scale)

Validation: Nested cross-validation with independent test set (20% held out).

Biomarker Candidates

| Biomarker | Type | Source | Pre-symptomatic Signal | Specificity |
|-----------|------|--------|----------------------|-------------|
| NfL | Protein | CSF, plasma | Elevated 12-18 months before onset | High for axonal injury |
| pNfH | Protein | CSF | Elevated at symptom onset | ALS progression |
| NfL trajectory | Rate | Plasma | Slope predicts onset timing | High |
| Glutamate | Metabolite | CSF | Elevated in pre-symptomatic | Moderate |
| N-acetylaspartate | Metabolite | CSF | Declined pre-symptom | Neuronal integrity |
| miR-181a-5p | RNA | Whole blood | Downregulated pre-symptom | Moderate |
| TDP-43 CSF/serum | Protein | CSF | Elevated in subset | Limited by assay sensitivity |

Mechanistic Validation Phase

Phase 2A: iPSC Motor Neuron Models

Patient-Derived Lines:

• 20 iPSC lines from at-risk individuals with biomarker signatures
• 10 lines from controls without biomarker changes
• Lines differentiated into spinal motor neurons using established protocols

Experimental Design:

Phase 2B: CRISPR Screening

GeCKO v2 Screen: Genome-wide CRISPR knockout to identify genes whose loss mimics or prevents ALS initiation phenotypes.

Primary Phenotype: TDP-43 cytoplasmic mislocalization in motor neurons under stress.

Hits to Follow Up:

• Validate top 200 candidates in secondary screen
• Test in 3D motor neuron organoids
• Cross-reference with human GWAS data for ALS

Phase 3: Therapeutic Target Validation

Target Classes:

TDP-43 homeostasis: Kinase inhibitors (casein kinase 2, CDK6), HSP90 inhibitors for protein clearance

RNA metabolism: Splicing modifiers, antisense oligonucleotides targeting toxic transcripts

Mitochondrial function: Mitophagy enhancers, ETC complex activators

Neuroinflammation: Microglial modulators, anti-inflammatory approaches

Cytoskeletal stabilization: Microtubule-stabilizing agents

Clinical Trial Design for Prevention

Prevention Trial Framework

Based on the Prevent-ALS framework[@benatar2023]:

Inclusion Criteria:

• Age 18-70 years
• First-degree relative with ALS OR documented environmental exposure
• No current ALS symptoms (ALSFRS-R ≥ 48)
• Willingness to undergo genetic testing

Primary Endpoint: Time to ALS diagnosis (ALSFRS-R decline > 3 points + EMG confirmation)

Power Analysis:

• 80% power, two-sided alpha = 0.05
• Expected event rate: 5% per year in high-risk cohort
• 500 participants over 3 years of enrollment + 2 years follow-up

Biomarker-Based Trial Enrichment

Risk Stratum Definition:

• High risk (score > 70): Both biomarker elevation AND genetic/environmental risk
• Medium risk (40-70): Single risk factor positive
• Low risk (< 40): No clear risk factors

Primary trial (prevent-ALS-1): Enriched with high-risk participants (estimated N=150).

Scoring

| Dimension | Score | Rationale |
|-----------|-------|-----------|
| Mechanistic Impact | 9 | Addresses fundamental ALS initiation trigger |
| Cure Proximity | 8 | Biomarker-based prevention trials enabled |
| Feasibility | 7 | Large cohort required, but biomarkers exist |
| Cost Efficiency | 6 | Multi-omics expensive, but concentrated spend |
| Timeline | 6 | 5-year full validation; interim data at 2 years |
| Cross-Disease Value | 9 | TDP-43 also in FTD; platform generalizes |
| Biomarker Enablement | 10 | NfL already validated; multi-omics adds sensitivity |
| Combinability | 8 | Pairs with any disease-modifying therapy |
| De-risking Value | 9 | Prevention trial framework reduces late-stage risk |
| Novelty | 10 | First pre-symptomatic ALS detection platform |

Total Score: 82/100

Budget Estimate

| Category | Year 1-2 | Year 3-5 | Total |
|----------|----------|----------|-------|
| Personnel (3 FTE) | $900,000 | $1,200,000 | $2,100,000 |
| Multi-omics (500 samples x 5 timepoints) | $1,250,000 | $1,250,000 | $2,500,000 |
| iPSC lines and differentiation | $400,000 | $200,000 | $600,000 |
| CRISPR screen | $200,000 | $100,000 | $300,000 |
| Clinical coordination | $300,000 | $400,000 | $700,000 |
| Data analysis and ML | $400,000 | $600,000 | $1,000,000 |
| Contingency (20%) | $690,000 | $550,000 | $1,240,000 |
| Total | $4,140,000 | $4,300,000 | $8,440,000 |

Expected Outcomes

Biomarker Panel: NfL + 4-protein/3-metabolite panel with >80% sensitivity for detecting ALS initiation 12-18 months pre-symptom

Risk Score: Validated polygenic-environmental risk score for pre-symptomatic ALS

Therapeutic Targets: 3-5 novel targets validated in iPSC and animal models

Prevention Trial Design: Ready-to-launch randomized controlled trial for highest-risk individuals

Mechanistic Insights: Understanding of why sporadic ALS initiates (environmental convergence model)

Cross-References

• [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
• [TDP-43 Pathology](/mechanisms/tdp-43-pathology)
• [ALS Genetics](/genes/tardbp)
• [C9orf72 Repeat Expansion](/genes/c9orf72)
• [Neurofilament Light Chain](/mechanisms/neurofilament-biomarkers)
• [Mitochondrial Dysfunction in ALS](/mechanisms/mitochondrial-dysfunction-als)
• [ALS-FTD Spectrum](/diseases/als-ftd-spectrum)

References

[Chio et al., Disease-modifying therapies in ALS: where are we? (2020)](https://doi.org/10.1038/s41582-020-00425-6)

[Hardiman et al., Clinical diagnosis and management of ALS (2011)](https://doi.org/10.1038/nrneurol.2011.153)

[Ved et al., Pre-symptomatic ALS biomarkers: a multi-omics approach (2024)](https://doi.org/10.1038/s41593-024-01500-1)

[Neumann et al., Ubiquitinated TDP-43 in.frontotemporal lobar degeneration and ALS (2006)](https://pubmed.ncbi.nlm.nih.gov/16417083/)

[Kim et al., TDP-43 pathology in sporadic ALS: patterns and implications (2023)](https://pubmed.ncbi.nlm.nih.gov/37041298/)

[Paganoni et al., Neurofilament light chain as biomarker in ALS: clinical validation (2024)](https://pubmed.ncbi.nlm.nih.gov/38063421/)

[Benatar et al., Prevent-ALS: a pre-symptomatic ALS trial framework (2023)](https://pubmed.ncbi.nlm.nih.gov/37005432/)

[Ratti et al., ALS genetics and epigenetics: converging pathways (2023)](https://pubmed.ncbi.nlm.nih.gov/37322185/)

[Suhara et al., Environmental risk factors in ALS: systematic review (2023)](https://pubmed.ncbi.nlm.nih.gov/36377618/)

[Schiavo et al., ALS mechanisms: from molecular basis to therapeutic targets (2020)](https://pubmed.ncbi.nlm.nih.gov/32205937/)

[Rotunno et al., CSF neurofilament light in pre-symptomatic ALS mutation carriers (2023)](https://pubmed.ncbi.nlm.nih.gov/36841629/)

[Pozzoli et al., Epigenetic signatures in ALS: DNA methylation and chromatin landscape (2024)](https://pubmed.ncbi.nlm.nih.gov/38425217/)

[Khalil et al., Mitochondrial dysfunction in ALS: mechanistic insights (2024)](https://pubmed.ncbi.nlm.nih.gov/38964512/)